Subsidy Information and Financing Scheme MSHLTalazoparib Capsule 0.25 mg, 1 mg Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in ... See all × MSHLTalazoparib Capsule 0.25 mg, 1 mg Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.
Drug Guidance for Subsidy 16/09/2025 Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combinat... See all × 16/09/2025 Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex. 12/07/2022 Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer The Ministry of Health’s Drug Advisory Committee has recommended: Olaparib 100 mg and 150 mg ... See all × 12/07/2022 Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer The Ministry of Health’s Drug Advisory Committee has recommended: Olaparib 100 mg and 150 mg tablets for treating germline BRCA-mutated, human epidermal growth factor receptor (HER2) negative, locally advanced or metastatic breast cancer in patients who have been previously treated with chemotherapy. Subsidy status ROlaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022. NRMAF assistance does not apply to olaparib 50 mg capsules or any formulations or strengths of talazoparib for treating BRCA-mutated, HER2-negative advanced breast cancer. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 0.25 mg National Cancer Centre Capsule 1 mg National Cancer Centre
ORAL Select a brand starting with the letter: T TALZENNA CAPSULE 0.1MG [SIN17238P] TALZENNA CAPSULE 0.25MG [SIN15944P] TALZENNA CAPSULE 0.35MG [SIN17239P] See all TALZENNA CAPSULE 0.5MG [SIN17240P] TALZENNA CAPSULE 1MG [SIN15945P]